These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 33582389)

  • 1.
    Chen X; Zhang Q; Zhang Y; Fang J; Jiang D; Mou Z; Liu H; Su R; Wang C; He F; Chen X; Xie F; Pan X; Li Z
    Eur J Med Chem; 2021 Mar; 214():113245. PubMed ID: 33582389
    [No Abstract]   [Full Text] [Related]  

  • 2. Development and biological evaluation of[
    Malik N; Kornelsen R; McCormick S; Colpo N; Merkens H; Bendre S; Benard F; Sossi V; Schirrmacher R; Schaffer P
    Eur J Med Chem; 2021 Feb; 211():113005. PubMed ID: 33248850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and Preliminary Evaluation of [
    Chen Z; Shao T; Gao W; Fu H; Collier TL; Rong J; Deng X; Yu Q; Zhang X; Davenport AT; Daunais JB; Wey HY; Shao Y; Josephson L; Qiu WW; Liang S
    ChemMedChem; 2019 Sep; 14(17):1580-1585. PubMed ID: 31365783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evaluation of Novel Positron Emission Tomography (PET) Probes for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2).
    Chen Z; Chen J; Mori W; Yi Y; Rong J; Li Y; Leon ERC; Shao T; Song Z; Yamasaki T; Ishii H; Zhang Y; Kokufuta T; Hu K; Xie L; Josephson L; Van R; Shao Y; Factor S; Zhang MR; Liang SH
    J Med Chem; 2024 Feb; 67(4):2559-2569. PubMed ID: 38305157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Synthesis of Pyrrolo[2,3-
    Williamson DS; Smith GP; Mikkelsen GK; Jensen T; Acheson-Dossang P; Badolo L; Bedford ST; Chell V; Chen IJ; Dokurno P; Hentzer M; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Wang Y; Christensen KV
    J Med Chem; 2021 Jul; 64(14):10312-10332. PubMed ID: 34184879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging Leucine-Rich Repeat Kinase 2 In Vivo with
    Chen Z; Chen J; Chen L; Yoo CH; Rong J; Fu H; Shao T; Coffman K; Steyn SJ; Davenport AT; Daunais JB; Haider A; Collier L; Josephson L; Wey HY; Zhang L; Liang SH
    J Med Chem; 2023 Feb; 66(3):1712-1724. PubMed ID: 36256881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulated Wnt and NFAT signaling in a Parkinson's disease LRRK2 G2019S knock-in model.
    Wetzel A; Lei SH; Liu T; Hughes MP; Peng Y; McKay T; Waddington SN; Grannò S; Rahim AA; Harvey K
    Sci Rep; 2024 May; 14(1):12393. PubMed ID: 38811759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
    Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and In Vitro and In Vivo Evaluation of [
    Malik N; Gifford AN; Sandell J; Tuchman D; Ding YS
    Mol Imaging Biol; 2017 Dec; 19(6):837-845. PubMed ID: 28289968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tale of proteolysis targeting chimeras (PROTACs) for Leucine-Rich Repeat Kinase 2 (LRRK2).
    Konstantinidou M; Oun A; Pathak P; Zhang B; Wang Z; Ter Brake F; Dolga AM; Kortholt A; Dömling A
    ChemMedChem; 2021 Mar; 16(6):959-965. PubMed ID: 33278061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
    Henderson JL; Kormos BL; Hayward MM; Coffman KJ; Jasti J; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD; Galatsis P
    J Med Chem; 2015 Jan; 58(1):419-32. PubMed ID: 25353650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions.
    Thomas JM; Wang X; Guo G; Li T; Dai B; Nucifora LG; Nucifora FC; Liu Z; Xue F; Liu C; Ross CA; Smith WW
    J Cell Physiol; 2020 Oct; 235(10):7309-7320. PubMed ID: 32180220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.
    Mendivil-Perez M; Velez-Pardo C; Jimenez-Del-Rio M
    Neurochem Res; 2016 Oct; 41(10):2675-2692. PubMed ID: 27394417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
    Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
    J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.